Britain’s biggest drugmaker’s latest acquisition will help it to develop new radiotherapy treatments
Business live – latest updates
Britain’s biggest drugmaker, AstraZeneca, is to buy a Canadian cancer specialist focused on next-generation treatments for $2.4bn (£1.9bn), the latest in a string of acquisitions made to strengthen its portfolio of new medicines.
The Anglo-Swedish company struck an agreement to acquire Fusion Pharmaceuticals, which is developing next-generation radioconjugates that offer an alternative to chemotherapy and radiotherapy. It has emerged as a new type of cancer treatment in recent years, and delivers a radioactive isotope directly to cancer cells through precise targeting using molecules such as antibodies, peptides or small molecules.
About Author
More Stories
I keep fantasising about living in total solitude in a forest
Microsoft unveils chip it says could bring quantum computing within years
Five years on from the pandemic, the right’s fake Covid narrative has been turbo-charged into the mainstream | Laura Spinney